Acarix A/S
The answer first
Does Acarix beat the market?
No, Acarix has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 14% of Nordic stocks
- Quality78
- Value3
- Trend10
No. 150 of 195 in healthcare
Max for seven days
Follow Acarix with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Acarix
Your first answer is free, no account needed.
Do you own Acarix, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Acarix and a few more. Free, no card.
Super Stock+45.9%In short
- Acarix has fallen 41.3% over the past year, including dividends.
- Overall, Acarix ranks better than 14% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 88.7%. The price is 98.6% below its peak now.
What do analysts think of Acarix?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 14% of Nordic stocks.
No. 150 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 59 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.23
- Return on equityProfit divided by equity−99.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 175 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity5.1
- P/SPrice divided by sales20.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 157 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−30.7%
- 6 months−40.4%
- 9 months−47.2%
- 12 months−41.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Acarix
One fund we follow owns Acarix. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Acarix
Acarix A/S is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 8 employees.
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.


See the full analysis of Acarix.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card